 | • レポートコード：MRC2Q12-19251 • 出版社/出版日：QYResearch / 2022年12月 • レポート形態：英文、PDF、125ページ • 納品方法：Eメール（納期：3営業日） • 産業分類：医薬品＆医療 |
| Single User | ￥725,200 (USD4,900) | ▷ お問い合わせ |
| Enterprise License | ￥1,450,400 (USD9,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 新型コロナウイルス感染症とロシア・ウクライナ戦争の影響により、おたふくかぜワクチンのグローバル市場は 2022にxxxドルと推定され、2028年までにxxxドルの規模に達し、2022年から2028年の予測期間中にxxx%のCAGRで成長すると予測されています。 おたふくかぜワクチンのアメリカ市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。 おたふくかぜワクチンの中国市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。 おたふくかぜワクチンのヨーロッパ市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。 生産面において、本レポートは2017年から2022年までのおたふくかぜワクチンの生産、成長率、メーカー別市場シェア、地域別市場シェア、および2028年までの予測を調査しています。販売面において、本レポートは2017年から2022年までの地域別、企業別、タイプ別、アプリケーション別のおたふくかぜワクチンの売上および2028年までの予測に焦点を当てています。 おたふくかぜワクチンのグローバル主要企業には、MedImmune、Johnson & Johnson、Merck & Co., Inc.、Sanofi、Serum Institute of India、Bavarian Nordic、Astellas Pharma India、CSL Limited、Emergent BioSolutions、GlaxoSmithKline、Panacea Biotec, Ltd.、Biological E Limited、Bharat Biotech Ltd.、Novavax, Inc.、Novartis、Sinovac Biotech, Ltd.、Incepta Vaccine Limited、Valneva SE、VBI Vaccines、PT Bio Farmaなどがあります。2021年、世界のトップ5プレイヤーは売上ベースで約xxx％の市場シェアを占めています。 おたふくかぜワクチン市場は、タイプとアプリケーションによって区分されます。世界のおたふくかぜワクチン市場のプレーヤー、利害関係者、およびその他の参加者は、当レポートを有益なリソースとして使用することで優位に立つことができます。セグメント分析は、2017年～2028年期間のタイプ別およびアプリケーション別の販売量、売上、予測に焦点を当てています。 【タイプ別セグメント】 子供、大人 【アプリケーション別セグメント】 病院薬局、小売薬局 【掲載地域】 北米：アメリカ、カナダ ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア アジア太平洋：日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア 中南米：メキシコ、ブラジル、アルゼンチン 中東・アフリカ：トルコ、サウジアラビア、UAE 【目次（一部）】 ・調査の範囲 - おたふくかぜワクチン製品概要 - タイプ別市場（子供、大人） - アプリケーション別市場（病院薬局、小売薬局） - 調査の目的 ・エグゼクティブサマリー - 世界のおたふくかぜワクチン販売量予測2017-2028 - 世界のおたふくかぜワクチン売上予測2017-2028 - おたふくかぜワクチンの地域別販売量 - おたふくかぜワクチンの地域別売上 - 北米市場 - ヨーロッパ市場 - アジア太平洋市場 - 中南米市場 - 中東・アフリカ市場 ・メーカーの競争状況 - 主要メーカー別おたふくかぜワクチン販売量 - 主要メーカー別おたふくかぜワクチン売上 - 主要メーカー別おたふくかぜワクチン価格 - 競争状況の分析 - 企業M&A動向 ・タイプ別市場規模（子供、大人） - おたふくかぜワクチンのタイプ別販売量 - おたふくかぜワクチンのタイプ別売上 - おたふくかぜワクチンのタイプ別価格 ・アプリケーション別市場規模（病院薬局、小売薬局） - おたふくかぜワクチンのアプリケーション別販売量 - おたふくかぜワクチンのアプリケーション別売上 - おたふくかぜワクチンのアプリケーション別価格 ・北米市場 - 北米のおたふくかぜワクチン市場規模（タイプ別、アプリケーション別） - 主要国別のおたふくかぜワクチン市場規模（アメリカ、カナダ） ・ヨーロッパ市場 - ヨーロッパのおたふくかぜワクチン市場規模（タイプ別、アプリケーション別） - 主要国別のおたふくかぜワクチン市場規模（ドイツ、フランス、イギリス、イタリア、ロシア） ・アジア太平洋市場 - アジア太平洋のおたふくかぜワクチン市場規模（タイプ別、アプリケーション別） - 主要国別のおたふくかぜワクチン市場規模（日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア） ・中南米市場 - 中南米のおたふくかぜワクチン市場規模（タイプ別、アプリケーション別） - 主要国別のおたふくかぜワクチン市場規模（メキシコ、ブラジル、アルゼンチン） ・中東・アフリカ市場 - 中東・アフリカのおたふくかぜワクチン市場規模（タイプ別、アプリケーション別） - 主要国別のおたふくかぜワクチン市場規模（トルコ、サウジアラビア） ・企業情報 MedImmune、Johnson & Johnson、Merck & Co., Inc.、Sanofi、Serum Institute of India、Bavarian Nordic、Astellas Pharma India、CSL Limited、Emergent BioSolutions、GlaxoSmithKline、Panacea Biotec, Ltd.、Biological E Limited、Bharat Biotech Ltd.、Novavax, Inc.、Novartis、Sinovac Biotech, Ltd.、Incepta Vaccine Limited、Valneva SE、VBI Vaccines、PT Bio Farma ・産業チェーン及び販売チャネル分析 - おたふくかぜワクチンの産業チェーン分析 - おたふくかぜワクチンの原材料 - おたふくかぜワクチンの生産プロセス - おたふくかぜワクチンの販売及びマーケティング - おたふくかぜワクチンの主要顧客 ・マーケットドライバー、機会、課題、リスク要因分析 - おたふくかぜワクチンの産業動向 - おたふくかぜワクチンのマーケットドライバー - おたふくかぜワクチンの課題 - おたふくかぜワクチンの阻害要因 ・主な調査結果 |
The MMR vaccine is a vaccine against measles, mumps, and rubella (German measles). The first dose is generally given to children around 9 months to 15 months of age, with a second dose at 15 months to 6 years of age, with at least 4 weeks between the doses.
Market Analysis and Insights: Global Mumps Vaccine Market
Due to the COVID-19 pandemic, the global Mumps Vaccine market size is estimated to be worth US$ million in 2022 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the forecast period 2022-2028. Fully considering the economic change by this health crisis, Child accounting for % of the Mumps Vaccine global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR from 2022 to 2028. While Hospitals Pharmacies segment is altered to an % CAGR throughout this forecast period.
China Mumps Vaccine market size is valued at US$ million in 2021, while the US and Europe Mumps Vaccine are US$ million and US$ million, severally. The proportion of the US is % in 2021, while China and Europe are % and % respectively, and it is predicted that China proportion will reach % in 2028, trailing a CAGR of % through the analysis period 2022-2028. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR %, %, and % respectively for the next 6-year period. As for the Europe Mumps Vaccine landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period 2022-2028.
The global key manufacturers of Mumps Vaccine include MedImmune, Johnson & Johnson, Merck & Co., Inc., Sanofi, Serum Institute of India, Bavarian Nordic, Astellas Pharma India, CSL Limited and Emergent BioSolutions, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
Global Mumps Vaccine Scope and Segment
Mumps Vaccine market is segmented by Type and by Application. Players, stakeholders, and other participants in the global Mumps Vaccine market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2017-2028.
Segment by Type
Child
Adult
Segment by Application
Hospitals Pharmacies
Retail Pharmacies
By Company
MedImmune
Johnson & Johnson
Merck & Co., Inc.
Sanofi
Serum Institute of India
Bavarian Nordic
Astellas Pharma India
CSL Limited
Emergent BioSolutions
GlaxoSmithKline
Panacea Biotec, Ltd.
Biological E Limited
Bharat Biotech Ltd.
Novavax, Inc.
Novartis
Sinovac Biotech, Ltd.
Incepta Vaccine Limited
Valneva SE
VBI Vaccines
PT Bio Farma
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
1 Study Coverage
1.1 Mumps Vaccine Product Introduction
1.2 Market by Type
1.2.1 Global Mumps Vaccine Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 Child
1.2.3 Adult
1.3 Market by Application
1.3.1 Global Mumps Vaccine Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Hospitals Pharmacies
1.3.3 Retail Pharmacies
1.4 Study Objectives
1.5 Years Considered
2 Executive Summary
2.1 Global Mumps Vaccine Sales Estimates and Forecasts 2017-2028
2.2 Global Mumps Vaccine Revenue Estimates and Forecasts 2017-2028
2.3 Global Mumps Vaccine Revenue by Region: 2017 VS 2021 VS 2028
2.4 Global Mumps Vaccine Sales by Region
2.4.1 Global Mumps Vaccine Sales by Region (2017-2022)
2.4.2 Global Sales Mumps Vaccine by Region (2023-2028)
2.5 Global Mumps Vaccine Revenue by Region
2.5.1 Global Mumps Vaccine Revenue by Region (2017-2022)
2.5.2 Global Mumps Vaccine Revenue by Region (2023-2028)
2.6 North America
2.7 Europe
2.8 Asia-Pacific
2.9 Latin America
2.10 Middle East & Africa
3 Competition by Manufacturers
3.1 Global Mumps Vaccine Sales by Manufacturers
3.1.1 Global Top Mumps Vaccine Manufacturers by Sales (2017-2022)
3.1.2 Global Mumps Vaccine Sales Market Share by Manufacturers (2017-2022)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Mumps Vaccine in 2021
3.2 Global Mumps Vaccine Revenue by Manufacturers
3.2.1 Global Mumps Vaccine Revenue by Manufacturers (2017-2022)
3.2.2 Global Mumps Vaccine Revenue Market Share by Manufacturers (2017-2022)
3.2.3 Global Top 10 and Top 5 Companies by Mumps Vaccine Revenue in 2021
3.3 Global Mumps Vaccine Sales Price by Manufacturers (2017-2022)
3.4 Analysis of Competitive Landscape
3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Mumps Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4.3 Global Mumps Vaccine Manufacturers Geographical Distribution
3.5 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global Mumps Vaccine Sales by Type
4.1.1 Global Mumps Vaccine Historical Sales by Type (2017-2022)
4.1.2 Global Mumps Vaccine Forecasted Sales by Type (2023-2028)
4.1.3 Global Mumps Vaccine Sales Market Share by Type (2017-2028)
4.2 Global Mumps Vaccine Revenue by Type
4.2.1 Global Mumps Vaccine Historical Revenue by Type (2017-2022)
4.2.2 Global Mumps Vaccine Forecasted Revenue by Type (2023-2028)
4.2.3 Global Mumps Vaccine Revenue Market Share by Type (2017-2028)
4.3 Global Mumps Vaccine Price by Type
4.3.1 Global Mumps Vaccine Price by Type (2017-2022)
4.3.2 Global Mumps Vaccine Price Forecast by Type (2023-2028)
5 Market Size by Application
5.1 Global Mumps Vaccine Sales by Application
5.1.1 Global Mumps Vaccine Historical Sales by Application (2017-2022)
5.1.2 Global Mumps Vaccine Forecasted Sales by Application (2023-2028)
5.1.3 Global Mumps Vaccine Sales Market Share by Application (2017-2028)
5.2 Global Mumps Vaccine Revenue by Application
5.2.1 Global Mumps Vaccine Historical Revenue by Application (2017-2022)
5.2.2 Global Mumps Vaccine Forecasted Revenue by Application (2023-2028)
5.2.3 Global Mumps Vaccine Revenue Market Share by Application (2017-2028)
5.3 Global Mumps Vaccine Price by Application
5.3.1 Global Mumps Vaccine Price by Application (2017-2022)
5.3.2 Global Mumps Vaccine Price Forecast by Application (2023-2028)
6 North America
6.1 North America Mumps Vaccine Market Size by Type
6.1.1 North America Mumps Vaccine Sales by Type (2017-2028)
6.1.2 North America Mumps Vaccine Revenue by Type (2017-2028)
6.2 North America Mumps Vaccine Market Size by Application
6.2.1 North America Mumps Vaccine Sales by Application (2017-2028)
6.2.2 North America Mumps Vaccine Revenue by Application (2017-2028)
6.3 North America Mumps Vaccine Market Size by Country
6.3.1 North America Mumps Vaccine Sales by Country (2017-2028)
6.3.2 North America Mumps Vaccine Revenue by Country (2017-2028)
6.3.3 United States
6.3.4 Canada
7 Europe
7.1 Europe Mumps Vaccine Market Size by Type
7.1.1 Europe Mumps Vaccine Sales by Type (2017-2028)
7.1.2 Europe Mumps Vaccine Revenue by Type (2017-2028)
7.2 Europe Mumps Vaccine Market Size by Application
7.2.1 Europe Mumps Vaccine Sales by Application (2017-2028)
7.2.2 Europe Mumps Vaccine Revenue by Application (2017-2028)
7.3 Europe Mumps Vaccine Market Size by Country
7.3.1 Europe Mumps Vaccine Sales by Country (2017-2028)
7.3.2 Europe Mumps Vaccine Revenue by Country (2017-2028)
7.3.3 Germany
7.3.4 France
7.3.5 U.K.
7.3.6 Italy
7.3.7 Russia
8 Asia Pacific
8.1 Asia Pacific Mumps Vaccine Market Size by Type
8.1.1 Asia Pacific Mumps Vaccine Sales by Type (2017-2028)
8.1.2 Asia Pacific Mumps Vaccine Revenue by Type (2017-2028)
8.2 Asia Pacific Mumps Vaccine Market Size by Application
8.2.1 Asia Pacific Mumps Vaccine Sales by Application (2017-2028)
8.2.2 Asia Pacific Mumps Vaccine Revenue by Application (2017-2028)
8.3 Asia Pacific Mumps Vaccine Market Size by Region
8.3.1 Asia Pacific Mumps Vaccine Sales by Region (2017-2028)
8.3.2 Asia Pacific Mumps Vaccine Revenue by Region (2017-2028)
8.3.3 China
8.3.4 Japan
8.3.5 South Korea
8.3.6 India
8.3.7 Australia
8.3.8 China Taiwan
8.3.9 Indonesia
8.3.10 Thailand
8.3.11 Malaysia
9 Latin America
9.1 Latin America Mumps Vaccine Market Size by Type
9.1.1 Latin America Mumps Vaccine Sales by Type (2017-2028)
9.1.2 Latin America Mumps Vaccine Revenue by Type (2017-2028)
9.2 Latin America Mumps Vaccine Market Size by Application
9.2.1 Latin America Mumps Vaccine Sales by Application (2017-2028)
9.2.2 Latin America Mumps Vaccine Revenue by Application (2017-2028)
9.3 Latin America Mumps Vaccine Market Size by Country
9.3.1 Latin America Mumps Vaccine Sales by Country (2017-2028)
9.3.2 Latin America Mumps Vaccine Revenue by Country (2017-2028)
9.3.3 Mexico
9.3.4 Brazil
9.3.5 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Mumps Vaccine Market Size by Type
10.1.1 Middle East and Africa Mumps Vaccine Sales by Type (2017-2028)
10.1.2 Middle East and Africa Mumps Vaccine Revenue by Type (2017-2028)
10.2 Middle East and Africa Mumps Vaccine Market Size by Application
10.2.1 Middle East and Africa Mumps Vaccine Sales by Application (2017-2028)
10.2.2 Middle East and Africa Mumps Vaccine Revenue by Application (2017-2028)
10.3 Middle East and Africa Mumps Vaccine Market Size by Country
10.3.1 Middle East and Africa Mumps Vaccine Sales by Country (2017-2028)
10.3.2 Middle East and Africa Mumps Vaccine Revenue by Country (2017-2028)
10.3.3 Turkey
10.3.4 Saudi Arabia
11 Company Profiles
11.1 MedImmune
11.1.1 MedImmune Corporation Information
11.1.2 MedImmune Overview
11.1.3 MedImmune Mumps Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.1.4 MedImmune Mumps Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 MedImmune Recent Developments
11.2 Johnson & Johnson
11.2.1 Johnson & Johnson Corporation Information
11.2.2 Johnson & Johnson Overview
11.2.3 Johnson & Johnson Mumps Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.2.4 Johnson & Johnson Mumps Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 Johnson & Johnson Recent Developments
11.3 Merck & Co., Inc.
11.3.1 Merck & Co., Inc. Corporation Information
11.3.2 Merck & Co., Inc. Overview
11.3.3 Merck & Co., Inc. Mumps Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.3.4 Merck & Co., Inc. Mumps Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 Merck & Co., Inc. Recent Developments
11.4 Sanofi
11.4.1 Sanofi Corporation Information
11.4.2 Sanofi Overview
11.4.3 Sanofi Mumps Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.4.4 Sanofi Mumps Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Sanofi Recent Developments
11.5 Serum Institute of India
11.5.1 Serum Institute of India Corporation Information
11.5.2 Serum Institute of India Overview
11.5.3 Serum Institute of India Mumps Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.5.4 Serum Institute of India Mumps Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 Serum Institute of India Recent Developments
11.6 Bavarian Nordic
11.6.1 Bavarian Nordic Corporation Information
11.6.2 Bavarian Nordic Overview
11.6.3 Bavarian Nordic Mumps Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.6.4 Bavarian Nordic Mumps Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 Bavarian Nordic Recent Developments
11.7 Astellas Pharma India
11.7.1 Astellas Pharma India Corporation Information
11.7.2 Astellas Pharma India Overview
11.7.3 Astellas Pharma India Mumps Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.7.4 Astellas Pharma India Mumps Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.7.5 Astellas Pharma India Recent Developments
11.8 CSL Limited
11.8.1 CSL Limited Corporation Information
11.8.2 CSL Limited Overview
11.8.3 CSL Limited Mumps Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.8.4 CSL Limited Mumps Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.8.5 CSL Limited Recent Developments
11.9 Emergent BioSolutions
11.9.1 Emergent BioSolutions Corporation Information
11.9.2 Emergent BioSolutions Overview
11.9.3 Emergent BioSolutions Mumps Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.9.4 Emergent BioSolutions Mumps Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.9.5 Emergent BioSolutions Recent Developments
11.10 GlaxoSmithKline
11.10.1 GlaxoSmithKline Corporation Information
11.10.2 GlaxoSmithKline Overview
11.10.3 GlaxoSmithKline Mumps Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.10.4 GlaxoSmithKline Mumps Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.10.5 GlaxoSmithKline Recent Developments
11.11 Panacea Biotec, Ltd.
11.11.1 Panacea Biotec, Ltd. Corporation Information
11.11.2 Panacea Biotec, Ltd. Overview
11.11.3 Panacea Biotec, Ltd. Mumps Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.11.4 Panacea Biotec, Ltd. Mumps Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.11.5 Panacea Biotec, Ltd. Recent Developments
11.12 Biological E Limited
11.12.1 Biological E Limited Corporation Information
11.12.2 Biological E Limited Overview
11.12.3 Biological E Limited Mumps Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.12.4 Biological E Limited Mumps Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.12.5 Biological E Limited Recent Developments
11.13 Bharat Biotech Ltd.
11.13.1 Bharat Biotech Ltd. Corporation Information
11.13.2 Bharat Biotech Ltd. Overview
11.13.3 Bharat Biotech Ltd. Mumps Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.13.4 Bharat Biotech Ltd. Mumps Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.13.5 Bharat Biotech Ltd. Recent Developments
11.14 Novavax, Inc.
11.14.1 Novavax, Inc. Corporation Information
11.14.2 Novavax, Inc. Overview
11.14.3 Novavax, Inc. Mumps Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.14.4 Novavax, Inc. Mumps Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.14.5 Novavax, Inc. Recent Developments
11.15 Novartis
11.15.1 Novartis Corporation Information
11.15.2 Novartis Overview
11.15.3 Novartis Mumps Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.15.4 Novartis Mumps Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.15.5 Novartis Recent Developments
11.16 Sinovac Biotech, Ltd.
11.16.1 Sinovac Biotech, Ltd. Corporation Information
11.16.2 Sinovac Biotech, Ltd. Overview
11.16.3 Sinovac Biotech, Ltd. Mumps Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.16.4 Sinovac Biotech, Ltd. Mumps Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.16.5 Sinovac Biotech, Ltd. Recent Developments
11.17 Incepta Vaccine Limited
11.17.1 Incepta Vaccine Limited Corporation Information
11.17.2 Incepta Vaccine Limited Overview
11.17.3 Incepta Vaccine Limited Mumps Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.17.4 Incepta Vaccine Limited Mumps Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.17.5 Incepta Vaccine Limited Recent Developments
11.18 Valneva SE
11.18.1 Valneva SE Corporation Information
11.18.2 Valneva SE Overview
11.18.3 Valneva SE Mumps Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.18.4 Valneva SE Mumps Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.18.5 Valneva SE Recent Developments
11.19 VBI Vaccines
11.19.1 VBI Vaccines Corporation Information
11.19.2 VBI Vaccines Overview
11.19.3 VBI Vaccines Mumps Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.19.4 VBI Vaccines Mumps Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.19.5 VBI Vaccines Recent Developments
11.20 PT Bio Farma
11.20.1 PT Bio Farma Corporation Information
11.20.2 PT Bio Farma Overview
11.20.3 PT Bio Farma Mumps Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.20.4 PT Bio Farma Mumps Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.20.5 PT Bio Farma Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Mumps Vaccine Industry Chain Analysis
12.2 Mumps Vaccine Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Mumps Vaccine Production Mode & Process
12.4 Mumps Vaccine Sales and Marketing
12.4.1 Mumps Vaccine Sales Channels
12.4.2 Mumps Vaccine Distributors
12.5 Mumps Vaccine Customers
13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis
13.1 Mumps Vaccine Industry Trends
13.2 Mumps Vaccine Market Drivers
13.3 Mumps Vaccine Market Challenges
13.4 Mumps Vaccine Market Restraints
14 Key Findings in The Global Mumps Vaccine Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer